These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 19222618)
1. JUPITER: wake up and smell the coffee--the absolute and relative merits of statin use. Jackson G; Citrome L Int J Clin Pract; 2009 Mar; 63(3):347-8. PubMed ID: 19222618 [No Abstract] [Full Text] [Related]
2. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor]. Olsson AG Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435 [No Abstract] [Full Text] [Related]
3. The numbers are in: statins for the primary prevention of cardiovascular disease in women. Duvernoy CS; Blumenthal R Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993 [No Abstract] [Full Text] [Related]
5. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439 [No Abstract] [Full Text] [Related]
6. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects]. Håkansson J Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433 [No Abstract] [Full Text] [Related]
7. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study. Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734 [No Abstract] [Full Text] [Related]
8. JUPITER study highlights value of anti-inflammatory action of rosuvastatin. Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096 [No Abstract] [Full Text] [Related]
11. The JUPITER Trial: responding to the critics. Ridker PM; Glynn RJ Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837 [No Abstract] [Full Text] [Related]
12. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline]. Lubsen J Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438 [No Abstract] [Full Text] [Related]
13. Rosuvastatin in patients with elevated C-reactive protein. Jenny-Avital ER N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275 [No Abstract] [Full Text] [Related]
14. [The CORONA study]. Metra M; Zacá V; Nodari S; Cas LD; Maggioni AP G Ital Cardiol (Rome); 2008 Apr; 9(4):229-33. PubMed ID: 18543792 [No Abstract] [Full Text] [Related]
15. [JUPITER study (2). For now no reason to give statins to more people]. Koopmans RP Ned Tijdschr Geneeskd; 2009 Feb; 153(6):218-9. PubMed ID: 19271439 [No Abstract] [Full Text] [Related]
17. Rosuvastatin in patients with elevated C-reactive protein. Pierard LA N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277 [No Abstract] [Full Text] [Related]
18. What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease? Lin GM; Li YH; Chu KM; Han CL Int J Cardiol; 2011 Jun; 149(3):387. PubMed ID: 21450359 [No Abstract] [Full Text] [Related]
19. [JUPITER study, more reason to give statins as preventive measure - commentary]. Narkiewicz K Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067 [No Abstract] [Full Text] [Related]
20. High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study. Targher G Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1251-2. PubMed ID: 21593456 [No Abstract] [Full Text] [Related] [Next] [New Search]